PURPOSE: Survival from Wilms Tumor (WT) exceeds 90% at 5 years in developed nations, whereas at last report, 2-year event-free survival (EFS) in Kenya reached only 35%. To clarify factors linked to these poor outcomes in Kenya, we established a comprehensive web-based WT registry, comprised of patients from the four primary hospitals treating childhood cancers. MATERIALS AND METHODS: WT patients diagnosed between January 2008 and January 2012 were identified. Files were abstracted for demographic characteristics, treatment regimens, and enrollment in the Kenyan National Hospital Insurance Fund (NHIF). Children under 15 years of age having both a primary kidney tumor on imaging and concordant histology consistent with WT were included. RESULTS: Two-year event-free survival (EFS) was 52.7% for all patients (n=133), although loss to follow up (LTFU) was 50%. For the 33 patients who completed all scheduled standard therapy, 2-year EFS was 94%. Patients enrolled in NHIF tended to complete more standard therapy and had a lower hazard of death (Cox 0.192, p < 0.001). CONCLUSION: Survival of Kenyan WT patients has increased slightly since last report. Notably, WT patients completing all phases of standard therapy experienced 2-year survival approaching the benchmarks of developed nations. Efforts in Kenya should be made to enhance compliance with WT treatment through NHIF enrollment.
PURPOSE: Survival from Wilms Tumor (WT) exceeds 90% at 5 years in developed nations, whereas at last report, 2-year event-free survival (EFS) in Kenya reached only 35%. To clarify factors linked to these poor outcomes in Kenya, we established a comprehensive web-based WT registry, comprised of patients from the four primary hospitals treating childhood cancers. MATERIALS AND METHODS: WT patients diagnosed between January 2008 and January 2012 were identified. Files were abstracted for demographic characteristics, treatment regimens, and enrollment in the Kenyan National Hospital Insurance Fund (NHIF). Children under 15 years of age having both a primary kidney tumor on imaging and concordant histology consistent with WT were included. RESULTS: Two-year event-free survival (EFS) was 52.7% for all patients (n=133), although loss to follow up (LTFU) was 50%. For the 33 patients who completed all scheduled standard therapy, 2-year EFS was 94%. Patients enrolled in NHIF tended to complete more standard therapy and had a lower hazard of death (Cox 0.192, p < 0.001). CONCLUSION: Survival of Kenyan WT patients has increased slightly since last report. Notably, WT patients completing all phases of standard therapy experienced 2-year survival approaching the benchmarks of developed nations. Efforts in Kenya should be made to enhance compliance with WT treatment through NHIF enrollment.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Jason Axt; Andrew J Murphy; Erin H Seeley; Colin A Martin; Chase Taylor; Janene Pierce; Richard M Caprioli; Martin Whiteside; Harold N Lovvorn Journal: J Surg Res Date: 2011-03-31 Impact factor: 2.192
Authors: K Ford; S Gunawardana; E Manirambona; G S Philipoh; B Mukama; A Kanyamuhunga; P Cartledge; M J Nyoni; D Mwaipaya; J Mpwaga; Z Bokhary; T Scanlan; T Heinsohn; H Hathaway; R Mansfield; S Wilson; K Lakhoo Journal: World J Surg Date: 2020-01 Impact factor: 3.352
Authors: Jaime Libes; Oliver Oruko; Fatmah Abdallah; Jessie Githanga; James Ndung'u; Joyce Musimbi; Festus Njuguna; Kirtika Patel; John White; Jason R Axt; James A O'Neill; Martha Shrubsole; Ming Li; Harold N Lovvorn Journal: Pediatr Blood Cancer Date: 2014-11-08 Impact factor: 3.167
Authors: Jaime M Libes; Erin H Seeley; Ming Li; Jason R Axt; Janene Pierce; Hernan Correa; Mark Newton; Erik Hansen; Audra Judd; Hayes McDonald; Richard M Caprioli; Arlene Naranjo; Vicki Huff; James A O'Neill; Harold N Lovvorn Journal: J Am Coll Surg Date: 2014-01-24 Impact factor: 6.113
Authors: Hannah M Phelps; Janene M Pierce; Andrew J Murphy; Hernan Correa; Jun Qian; Pierre P Massion; Harold N Lovvorn Journal: J Pediatr Surg Date: 2019-02-28 Impact factor: 2.545
Authors: Harold N Lovvorn; Janene Pierce; Jaime Libes; Bingshan Li; Qiang Wei; Hernan Correa; Julia Gouffon; Peter E Clark; Jason R Axt; Erik Hansen; Mark Newton; James A O'Neill Journal: Genes Chromosomes Cancer Date: 2015-08-14 Impact factor: 5.006